نتایج جستجو برای: شرکت merck
تعداد نتایج: 54045 فیلتر نتایج به سال:
Background. ISENTRESS (raltegravir, RAL) is licensed for 400 mg b.i.d. use. An investigational 1200 mg q.d. regimen for reformulated raltegravir (re-RAL) is under clinical development. This study assessed the safety and pharmacokinetics (PK) of a higher dose of re-RAL. Methods. A double-blind, multiple-dose, randomized, fully domiciled study assessed the safety and PK of 1800 mg dose of re-RAL ...
Department of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; Rosetta Inpharmatics, LLC, Merck & Co., Inc., Seattle, WA 98109; Quellos High Throughput Screening Core, Department of Pharmacology, Institute for Stem Cells and Regenerative Medicine and Seattle Children’s Hospital and Department of Pediatrics, University of Washington, Seattle, WA 98109; and Merck & Co., W...
MICs of tigecycline determined by Etest were 4 to 12 times (three ATCC strains) and 2 to 8 times (50 clinical isolates) higher in Mueller-Hinton agar from Merck than in Mueller-Hinton agar from either Oxoid or Difco. This was related to a much higher concentration of manganese in the medium from Merck.
Canada Research Chair on Electroactive a Chemistry, Université Laval, Quebec City, Q [email protected] Department of Chemistry, Université Laval, Department of Chemical Engineering, Unive 3G1, Canada Merck Chemicals Ltd, Chilworth Technical Merck KGaA, Darmstadt, Germany) † Electronic supplementary information 1507661. For ESI and crystallographic dat DOI: 10.1039/c7sc00589j ‡ T. Bura and S...
Employment or Leadership: None declared. Consultant or Advisory Role: None declared. Stock Ownership: None declared. Honoraria: E. Giannitsis, Merck Sharp & Dohme, Lilly, Bristol Myers Squibb, GlaxoSmithKline, Roche Diagnostics, and Bayer; H.J. Roth, Merck Sharp & Dohme and Roche Diagnostics. Research Funding: E. Giannitsis received funds and access to assays from Roche Diagnostics. Expert Test...
Funding Editorial support was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Conflict of interest: G.K.H.: none declared; M.H.D.: acted as consultant/advisory board member for Amgen, AstraZeneca, Merck, and Sanofi-Aventis and a stockholder in Omthera Pharmaceuticals, Inc.; J.J.P.K.: a consultant to Regeneron, Sanofi, Eli Lilly, Amgen, Aegerion, Merck, Isis, Genzyme, Novartis, Kowa; A.M.O....
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید